8-K/ALeadership Changes

BRISTOL MYERS SQUIBB CO 8-K/A Report, Executive Changes (Mar 6, 2015)

Filed March 6, 2015For Securities:BMYCELG-RIBMYMP

Summary

This amended 8-K filing by Bristol-Myers Squibb (BMY) provides crucial updates regarding executive leadership changes and compensation, primarily focused on the transition of CEO Lamberto Andreotti to Executive Chairman and the appointment of Giovanni Caforio, M.D., as the new CEO, effective May 5, 2015. The report details Dr. Caforio's new compensation package, including a significant base salary, annual bonus target, and substantial long-term incentive awards. It also outlines the compensation structure for Mr. Andreotti's new roles as Executive Chairman and later Non-Executive Chairman, emphasizing a transitional period and standard director compensation thereafter. Investors should note the clear succession plan and the associated compensation adjustments designed to incentivize the new CEO and manage the transition. The compensation for Dr. Caforio reflects a typical structure for a CEO role, with performance-based incentives tied to corporate goals and long-term equity awards. The detailed breakdown of Mr. Andreotti's compensation as he moves to board roles provides clarity on the financial implications of his evolving responsibilities.

Key Highlights

  • 1Giovanni Caforio, M.D., appointed as the new Chief Executive Officer (CEO), effective May 5, 2015.
  • 2Lamberto Andreotti transitions from CEO to Executive Chairman of the Board, effective May 5, 2015, followed by a move to Non-Executive Chairman on August 3, 2015.
  • 3Dr. Caforio's new CEO compensation includes an annual base salary of $1,400,000.
  • 4Dr. Caforio is eligible for an annual bonus with a target opportunity of 150% of his base salary, based on corporate performance goals.
  • 5Dr. Caforio will receive long-term incentive awards valued at $5,234,894, structured with 60% in performance share units and 40% in market share units.
  • 6Mr. Andreotti will receive specific compensation for his Executive Chairman and transitional Non-Executive Chairman roles, with a shift to standard non-employee director compensation later.
  • 7James M. Cornelius retired from the Company's Board of Directors.

Frequently Asked Questions

The key leadership changes include the appointment of Giovanni Caforio, M.D., as the new Chief Executive Officer (CEO), effective May 5, 2015. Lamberto Andreotti will transition from CEO to Executive Chairman of the Board on May 5, 2015, and then to Non-Executive Chairman on August 3, 2015. James M. Cornelius also retired from the Board of Directors.

Dr. Caforio's compensation as CEO includes an annual base salary of $1,400,000. He is eligible for an annual bonus with a target of 150% of his base salary, tied to corporate performance. He will also receive long-term incentive awards valued at approximately $5.23 million, consisting of performance share units and market share units.

During his transition as Executive Chairman (effective May 5, 2015), Mr. Andreotti's salary and bonus opportunity will remain unchanged. For his role as Non-Executive Chairman (effective August 3, 2015), he will receive standard non-employee director compensation (annual retainer of $90,000 and deferred share units valued at $160,000), plus an additional annual Non-Executive Chairman retainer of $200,000 and a Transitional Non-Executive Chairman retainer of $225,000 annualized, with a portion paid in cash and a portion in company stock.

The filing indicates a clear succession plan with compensation structures designed to align executive incentives with company performance and strategic goals. The long-term incentive awards for the new CEO are performance-based, which generally aligns with shareholder interests. The transition of the former CEO to a board role suggests continued guidance during leadership changes.